LONDON (AFX) - SR Pharma PLC said its subsidiary Atugen AG has established
collaborations with Genzyme, BioSpring and OctoPlus to manufacture and formulate anti-cancer drug Atu027 to GMP standards.
Atu027 is on track to enter initial clinical trials in the first half of 2007. Establishing GMP manufacturing of this complex drug is a major step forward in the product's development and potential out-licensing.
COPYRIGHT Copyright AFX News Limited 2005. All rights reserved. The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News. AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.